Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate
    5.
    发明授权
    Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate 有权
    制备2-甲氧基异丁腈和四(2-甲氧基异丁基丁腈)四氟硼酸铜(I)的方法

    公开(公告)号:US08703987B2

    公开(公告)日:2014-04-22

    申请号:US12505054

    申请日:2009-07-17

    申请人: Pierre Morel

    发明人: Pierre Morel

    IPC分类号: C07C249/00

    摘要: The present invention relates to new synthetic methods for preparing 2-methoxyisobutylisonitrile and metal isonitrile complexes, such as tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate, which are used in the preparation of technetium (99mTc) Sestamibi, and novel intermediate compounds useful in such methods.

    摘要翻译: 本发明涉及制备2-甲氧基异丁腈和金属异氰腈络合物的新型合成方法,例如用于制备锝(99mTc)西他咪胺的四(2-甲氧基异丁基丁腈)铜(I)四氟硼酸铜,以及有用的新型中间体化合物 在这样的方法。

    Composition, synthesis, and use of isonitriles
    8.
    发明授权
    Composition, synthesis, and use of isonitriles 有权
    异构体的组成,合成和使用

    公开(公告)号:US08269032B1

    公开(公告)日:2012-09-18

    申请号:US13080179

    申请日:2011-04-05

    IPC分类号: C07C249/00

    摘要: The present invention relates to isonitrile compounds, methods of synthesis, and uses in a variety of fields. In one aspect, the present invention includes sulfinyl methyl isonitriles and methods for their preparation. In another aspect, the present invention includes the use of sulfinyl methyl isonitriles to prepare various other isonitrile compounds and derivatives thereof. In yet another aspect, the present invention includes a relatively simple and routine synthesis of sulfinyl methyl isonitrile compounds, other isonitrile compounds and derivatives thereof.

    摘要翻译: 本发明涉及异腈化合物,合成方法和在各种领域中的应用。 一方面,本发明包括亚磺酰基甲基异腈及其制备方法。 另一方面,本发明包括使用亚磺酰基甲基异腈制备各种其它异腈化合物及其衍生物。 另一方面,本发明包括亚磺酰基甲基异腈化合物,其它异腈化合物及其衍生物的相对简单且常规的合成。

    Combination cancer therapy with bis(thiohydrazide) amide compounds
    10.
    发明授权
    Combination cancer therapy with bis(thiohydrazide) amide compounds 有权
    联合癌症治疗与双(硫代酰肼)酰胺化合物

    公开(公告)号:US08017654B2

    公开(公告)日:2011-09-13

    申请号:US11918357

    申请日:2006-04-13

    摘要: A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e.g., Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.

    摘要翻译: 用癌症治疗受试者的方法包括在三至五周内共同给予受试者的步骤,量为约243μmol/ m 3至315μmol/ m 2的紫杉烷(例如,相当于约210的紫杉醇 -270 mg / m2); 和约1473μmol/ m 2与约1722μmol/ m 2之间的量的二(硫代酰肼)酰胺(例如化合物(1),约590-690mg / m 2)。 双(硫代酰肼)由结构式(I)表示,Y为共价键或任选取代的直链烃基,或Y与它们所键合的两个> C = Z基团一起为 任选取代的芳族基团。 R 1 -R 4独立地是-H,任选取代的脂族基团,任选取代的芳基,或者R 1和R 3与它们所键合的碳原子和氮原子一起,和/或R 2和R 4与碳和 与它们键合的氮原子形成任选地与芳环稠合的非芳族杂环。 R 7 -R 8独立地为-H,任选取代的脂族基团或任选取代的芳基。 Z是O或S.